分组1 - Skillz Inc. reported a quarterly loss of $0.92 per share, better than the Zacks Consensus Estimate of a loss of $1.09, and an improvement from a loss of $1.45 per share a year ago, resulting in an earnings surprise of 15.60% [1] - The company posted revenues of $22.41 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.01%, although this represents a decline from year-ago revenues of $25.24 million [2] - Skillz shares have increased by approximately 3% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$1.25 on revenues of $20.5 million, and for the current fiscal year, it is -$4.74 on revenues of $86.95 million [7] - The Zacks Industry Rank indicates that the Gaming industry is currently in the bottom 41% of over 250 Zacks industries, suggesting that the industry's outlook may negatively impact stock performance [8]

分组1 - Willdan Group reported quarterly earnings of $0.63 per share, exceeding the Zacks Consensus Estimate of $0.44 per share, and up from $0.40 per share a year ago, representing an earnings surprise of 43.18% [1] - The company posted revenues of $85.34 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 15.24%, although this is a decrease from year-ago revenues of $122.49 million [2] - Willdan has outperformed the S&P 500, with shares increasing about 5.3% since the beginning of the year, while the S&P 500 has declined by -4.3% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.71 on revenues of $81.4 million, and for the current fiscal year, it is $2.75 on revenues of $323.7 million [7] - The Zacks Industry Rank places the Business - Services sector in the top 21% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - PDF Solutions (PDFS) reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.19 per share, and up from $0.15 per share a year ago [1] - The company experienced an earnings surprise of 10.53% and has surpassed consensus EPS estimates in all four of the last quarters [2] - Revenue for the quarter was $47.78 million, slightly missing the Zacks Consensus Estimate by 0.46%, but up from $41.31 million year-over-year [3] Earnings Performance - The earnings surprise of 10.53% indicates strong performance relative to expectations [2] - The company has consistently exceeded consensus EPS estimates over the last four quarters, showcasing a positive trend in earnings performance [2] Revenue Analysis - Revenue of $47.78 million for the quarter represents a year-over-year increase but fell short of expectations [3] - The company has topped consensus revenue estimates three times in the last four quarters, indicating a generally positive revenue trend despite the recent miss [3] Stock Performance - PDF Solutions shares have declined approximately 29.5% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [4] - The stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [4] Future Outlook - Current consensus EPS estimate for the upcoming quarter is $0.19 on revenues of $49.6 million, and for the current fiscal year, it is $0.87 on revenues of $205.1 million [8] - The estimate revisions trend for PDF Solutions is currently unfavorable, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [7] Industry Context - The Computer - Services industry, to which PDF Solutions belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable industry outlook [9] - The performance of PDF Solutions may be influenced by the overall industry trends, as top-ranked industries tend to outperform lower-ranked ones significantly [9]

Core Viewpoint - Assembly Biosciences reported a quarterly loss of $1.17 per share, significantly better than the Zacks Consensus Estimate of a loss of $2.01, indicating a positive earnings surprise of 41.79% [1] Financial Performance - The company posted revenues of $9.42 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 21.38%, compared to $5.79 million in the same quarter last year [2] - Over the last four quarters, Assembly Biosciences has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Assembly Biosciences shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The company's current Zacks Rank is 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.59 on revenues of $8.19 million, and for the current fiscal year, it is -$6.78 on revenues of $33.7 million [7] - The trend of estimate revisions for Assembly Biosciences is currently favorable, which could influence future stock movements [5][6] Industry Context - The Medical - Generic Drugs industry, to which Assembly Biosciences belongs, is currently ranked in the top 18% of over 250 Zacks industries, indicating a strong industry performance potential [8]

Company Performance - Crinetics Pharmaceuticals reported a quarterly loss of $1.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.99, and compared to a loss of $0.93 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $0.36 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 261%, but this was a decrease from year-ago revenues of $0.64 million [2] - Over the last four quarters, Crinetics has only surpassed consensus EPS estimates once, indicating inconsistent performance [2] Stock Movement and Outlook - Crinetics Pharmaceuticals shares have declined approximately 38.6% since the beginning of the year, significantly underperforming the S&P 500, which declined by only 4.3% [3] - The company's earnings outlook is uncertain, with current consensus EPS estimates for the upcoming quarter at -$1.10 on revenues of $2.6 million, and for the current fiscal year at -$4.33 on revenues of $5.63 million [7] Industry Context - The Medical - Drugs industry, to which Crinetics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - The performance of Crinetics may be influenced by the overall outlook for the industry, as empirical research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -44%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.27 per share when it actually produced a loss of $0.26, delivering a surprise of 3.70%.Over the last four quarters, the c ...

Company Performance - Flux Power Holdings, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, but an improvement from a loss of $0.16 per share a year ago, indicating a surprise of -33.33% [1] - The company posted revenues of $16.74 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.62% and showing an increase from $14.46 million in the same quarter last year [2] - Over the last four quarters, Flux Power has not surpassed consensus EPS estimates, but it has topped consensus revenue estimates twice [2] Stock Performance - Flux Power shares have increased by approximately 20.9% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [3] - The company's current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $16.61 million, and for the current fiscal year, it is -$0.36 on revenues of $65.9 million [7] Industry Outlook - The Electronics - Miscellaneous Products industry, to which Flux Power belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Flux Power's stock performance [5]

Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.77%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.86 per share when it actually produced earnings of $0.91, delivering a surprise of 5.81%.Over the last four quarters, the company ...

Core Viewpoint - Insulet (PODD) reported quarterly earnings of $1.02 per share, exceeding the Zacks Consensus Estimate of $0.81 per share, and showing an increase from $0.73 per share a year ago, indicating a strong performance in the insulin infusion systems market [1] Financial Performance - The company achieved revenues of $569 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.96% and up from $441.7 million in the same quarter last year [2] - Over the last four quarters, Insulet has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] Stock Performance - Insulet shares have increased by approximately 1.2% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] Future Outlook - The company's earnings outlook will be crucial for determining the stock's immediate price movement, with current consensus EPS estimates at $0.91 for the upcoming quarter and $4.28 for the current fiscal year [4][7] - The estimate revisions trend for Insulet is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which Insulet belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Performance - Texas Roadhouse reported quarterly earnings of $1.70 per share, missing the Zacks Consensus Estimate of $1.75 per share, representing an earnings surprise of -2.86% [1] - The company posted revenues of $1.45 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.53%, compared to year-ago revenues of $1.32 billion [2] - Over the last four quarters, Texas Roadhouse has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Movement and Outlook - Texas Roadhouse shares have lost about 5.1% since the beginning of the year, while the S&P 500 has declined by -4.3% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $1.95 for the coming quarter and $6.93 for the current fiscal year [4][7] - The current Zacks Rank for Texas Roadhouse is 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Retail - Restaurants industry, to which Texas Roadhouse belongs, is currently in the bottom 22% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can materially affect stock performance [5][8]